Antiviral Chemotherapy 4
New Directions for Clinical Application and Research
Series: Advances in Experimental Medicine and Biology; 394;
- Publisher's listprice EUR 213.99
-
88 752 Ft (84 526 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 20% (cc. 17 750 Ft off)
- Discounted price 71 002 Ft (67 621 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
88 752 Ft
Availability
Estimated delivery time: In stock at the publisher, but not at Prospero's office. Delivery time approx. 3-5 weeks.
Not in stock at Prospero.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Edition number 1996
- Publisher Springer US
- Date of Publication 31 March 1996
- Number of Volumes 1 pieces, Book
- ISBN 9780306452949
- Binding Hardback
- No. of pages440 pages
- Size 234x156 mm
- Weight 1810 g
- Language English
- Illustrations XIV, 440 p. Illustrations, black & white 0
Categories
Long description:
The three years since our last conference in San Francisco have again seen a dramatic expansion of the number of antivirals either licensed or in the late stages of clinical trials. d4T is now licensed for HIV infection, famciclovir and the oral pro-drug of acyclovir, valacyclovir, are now licensed for VZV infections in some countries. Moreover. oral ganciclovir, cidofovir, and sorivudine are not far behind. Clinical trials with the second-site reverse transcriptase inhibitors and the protease inhibitors for HlV infection are proceeding rapidly and on a broad scale, and the preliminary results would suggest that several of these classes of drugs will be licensed as well. Despite this optimism, however, there is increasing evidence that antiviral-resistant strains of pathogenic viruses will be a significant problem, perhaps especially with therapy of HIV infection, and there remains a desperate need for improved drugs (with either improved efficacy or decreased toxicity, or both) for CMV and HIV infections. This book is the edited proceedings of the Fourth Triennial Conference on Antiviral Chemotherapy, held in San Francisco, in November 1994. The conference was sponsored by the University of California, San Francisco, and co-sponsored by the International Society for Antiviral Research (ISAR), the Macfarlane Burnet Centre for Medical Research in Melbourne, Australia, and the Australian National Centre for HIV Virology Research. The conference had been organized to present an overview of the field of antiviral chemotherapy.
MoreTable of Contents:
Management of Genital Herpes.- Subclinical Shedding of HSV: Its Potential for Reduction by Antiviral Therapy.- Famciclovir: Efficacy in Zoster and Issues in the Assessment of Pain.- Valacyclovir Hcl (ValtrexTM): An Acyclovir Prodrug with Improved Pharmacokinetics and Better Efficacy for Treatment of Zoster.- Sorivudine: A Potent Inhibitor of Varicella Zoster Virus Replication.- Summary of Panel Discussion about Antiviral Therapy for Zoster.- Antiviral Drug Resistance in Herpes Simplex Virus.- Treatment of Acyclovir-Resistant Herpes Simplex and Varicella Zoster Virus Infections.- Therapeutic Immunization for Recurrent Herpes Simplex Virus Infections.- Current Management of Cytomegalovirus Retinitis in AIDS Update on Ganciclovir and Foscarnet for CMV Infections.- Oral Ganciclovir for Cytomegalovirus Infections.- A Preclinical and Clinical Overview of the Nucleotide-Based Antiviral Agent Cidofovir (HPMPC).- Prophylaxis and Treatment of CMV Infections in Transplantation.- Cytomegalovirus: Genetics of Drug Resistance.- Immunotherapy of CMV Infections.- Hantavirus Infections in the United States: Diagnosis and Treatment.- Management of Respiratory Syncytial Virus Infections.- Update on Therapy of Influenza and Rhinovirus Infections.- Therapy for Chronic Hepatitis B Infection.- Treatment of Chronic Hepatitis C Virus Infection: A Clinical and Virological Perspective.- Zidovudine: Anno 1995.- The Clinical Use of Didanosine.- ddC (Zalcitabine).- Stavudine (d4T, Zerit®).- Delavirdine Mesylate, a Potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitor.- Clinical Experience with Non-Nucleoside Reverse Transcriptase Inhibitors: L-697,661 and Nevirapine.- Current Clinical Experience with Nevirapine for HIV Infection.- Saquinavir: An HIV Proteinase Inhibitor.- Perspectives in HIVProtease Inhibitors.- In Vivo Selection of HIV-1 Variants with Reduced Susceptibility to the Protease Inhibitor L-735,524 and Related Compounds.- Controversies in Initiating Anti-Retroviral Therapy and in the Use of Combination Therapies.- Use of Antiretroviral Therapy in Children and Pregnant Women.- Efficacy of Combination Antiretroviral Therapy.- New Initiatives in Combination Antiretroviral Chemotherapy.- Antiretroviral Drug Resistance: Mechanisms, Pathogenesis, Clinical Significance.- Promising Anti-HIV Compounds in Preclinical or Early Clinical Development.- Enhancing HIV-1 Specific Immunity as a Therapeutic Strategy in AIDS.- Cytokine Therapy of HIV Infection.- Gene Therapy for HIV-1 Infection.
More
